Study of risk assessment scores as surrogate endpoints in pulmonary arterial hypertension trials
American Journal of Respiratory and Critical Care Medicine · 2026
DOI: 10.1093/ajrccm/aamaf003 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Respiratory and Critical Care Medicine, 2026. Verfasst von Yongqi Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Statistics, The Ohio State University, Columbus, OH, United States. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Rationale
Pulmonary arterial hypertension (PAH) clinical trials largely rely on clinically relevant intermediate outcomes, as mortality and lung transplant are infrequent and remote outcomes. The change in 6-minute walk distance (Δ6MWD) is utilized as an intermediate endpoint and is used as a surrogate for clinical worsening events.
Objectives
We investigate whether the change in 4 composite risk assessment scores—REVEAL Lite 2 (ΔRL2), European Four Strata (ΔE4), European Three Strata (ΔE3), and French Noninvasive score (ΔFPHN)—are potentially stronger surrogate endpoints than the single-component Δ6MWD in PAH studies.
Methods
Using data from the AMBITION and FREEDOM-EV trials, we estimated the percentage of treatment effect in reducing clinical worsening events within 1 year that is attributed to the change on each of the 5 scores between baseline and 12–16 weeks’ follow-up. We conducted bootstrap analysis to provide head-to-head comparisons. Measurements and Main Results Our analysis shows that all 4 composite scores mediate significantly more of the treatment effect compared to 6MWD (29% for ΔRL2 and ΔE4 compared to 19% for Δ6MWD; both P <10−15). The drug treatment effect accounted for by all 5 scores increases with intermediate/high-risk patients, and ΔRL2 had the highest % mediation (37% for ΔRL2 vs 28% for Δ6MWD; P < 10−15).
Conclusions
RL2 and E4 were the strongest mediators, with RL2 showing the highest mediation in intermediate/high-risk patients. Until better surrogates are found that mediate over 50% of the treatment effect, RL2 or E4 may serve as alternatives to the 6MWD as intermediate endpoints.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Statistics, The Ohio State University, Columbus, OH, United States.
- Division of Pulmonary and Critical Care Medicine, University of Rochester, NY, United States.
- Department of Cardiology, Rouen University Hospital, INSERM U1096, Rouen, France.
- Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York City, NY, United States.
ORCID-Profile: R James White, Charles Fauvel, Shili Lin, Raymond L Benza
Förderung
- NHLBI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Liu, Y., White, R. J., Lee, S. W., Fauvel, C., Correa-Jaque, P., Lin, S., & Benza, R. L. (2026). Study of risk assessment scores as surrogate endpoints in pulmonary arterial hypertension trials. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1093/ajrccm/aamaf003
Vancouver
Liu Y, White RJ, Lee SW, Fauvel C, Correa-Jaque P, Lin S, et al. Study of risk assessment scores as surrogate endpoints in pulmonary arterial hypertension trials. American Journal of Respiratory and Critical Care Medicine. 2026. doi:10.1093/ajrccm/aamaf003
BibTeX
@article{Liu2026,
author = {Liu, Yongqi and White, R James and Lee, Sang Wan and Fauvel, Charles and Correa-Jaque, Priscilla and Lin, Shili and Benza, Raymond L},
title = {Study of risk assessment scores as surrogate endpoints in pulmonary arterial hypertension trials},
journal = {American Journal of Respiratory and Critical Care Medicine},
year = {2026},
doi = {10.1093/ajrccm/aamaf003}
}
EUVIMED